Efficacy of cyclosporin in the treatment of atopic dermatitis in dogs--combined results from two veterinary dermatology referral centres.
OBJECTIVE
To evaluate the efficacy of cyclosporin in controlling the clinical signs associated with atopic dermatitis in dogs under Australian field conditions.


METHODS
A multicentre prospective clinical investigation of the use of cyclosporin in 41 dogs with atopic dermatitis.


METHODS
Dogs were treated with cyclosporin (5 mg/kg orally once daily with food) for 6 weeks. Four clinical parameters of severity of atopic dermatitis were measured on Day 0 and on Day 42 using a 0 to 4 scoring system. Individual variables were then combined to form a Global Score. Both client and clinician observed pruritus scores were combined to form a Pruritus Score. Pre- and post-treatment scores were statistically analysed. The difference in results between the two investigators was also recorded and analysed.


RESULTS
All dogs showed a marked reduction in pruritus and erythema during the 6-week treatment period. All dogs showed a significant (P < 0.001) improvement in clinical lesion scores and Global Score (P < 0.001). The mean percentage improvement in Global Score from Day 0 to Day 42 was 83.9%. The mean percentage improvement in Pruritus Score from Day 0 to Day 42 was 83%. The medication was well tolerated. Side effects such as vomiting, diarrhoea and soft stools were observed in four dogs. Another four dogs developed bacterial pyoderma during the trial period. There was no significant difference in results between the two centres.


CONCLUSIONS
Cyclosporin was well tolerated and efficacious in the symptomatic treatment of atopic dermatitis in dogs attending two veterinary dermatology referral centres in Australia, under Australian field conditions, when administered at 5 mg/kg/day for 6 weeks.
Melbourne Veterinary Referral Centre, 70 Blackburn Road, Glen Waverley, Victoria.
G
G
Burton
A
A
Burrows
R
R
Walker
D
D
Robson
R
R
Bassett
S
S
Bryden
A
A
Hill
D000284:Administration, Oral; D000818:Animals; D016572:Cyclosporine / Q000008:administration & dosage*; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000662:veterinary*; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D008297:Male; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014904:Western Australia
D003879:Dermatologic Agents; D016572:Cyclosporine